Physician profile
Devin Whitt
NPI 1821627068
$4,892.08
in general payments reported to CMS, 2019-2025
22 companies · $812 in 2025
The $812 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $1,068 · 2023: $1,219 · 2024: $1,164 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $1,323.01 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $958.06 | 2021-2025 | Aralast, Glassia, Cuvitru |
| Glaxosmithkline, LLC. | $852.13 | 2021-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.44 | 2022-2025 | Ofev |
| Mylan Specialty L.P. | $254.15 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $233.21 | 2021-2025 | Dupixent |
| Genzyme Corporation | $191.16 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $189.39 | 2022-2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $113.18 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Viatris Specialty LLC | $89.75 | 2025 | Yupelri |
| Verona Pharma, INC. | $89.67 | 2025 | Ohtuvayre |
| Amgen INC. | $79.78 | 2024-2025 | Tezspire, Repatha, Otezla |
| Baxter Healthcare | $44.74 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $37.26 | 2025 | Zerbaxa |
| Exact Sciences Corporation | $35.59 | 2024-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $26.81 | 2022 | |
| Pulmonx Corporation | $22.43 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Otsuka America Pharmaceutical, INC. | $18.56 | 2023 | Rexulti, Abilify Maintena |
| Adma Biomanufacturing LLC | $18.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2024 | |
| Vifor Pharma, INC. | $14.74 | 2024 | Zemaira |
| United Therapeutics Corporation | $13.74 | 2024 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Whitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.